TFAM: why more is not always better for aging mitochondria

The hunt for therapies built on TFAM upregulation—the mitochondrial transcription factor crucial for DNA maintenance—looked promising two decades ago, but the biochemistry proved deceptively complex. Recent research shows TFAM is no simple hero: its effects depend critically on protein abundance, stoichiometry with mitochondrial DNA, tissue type, and metabolic state. TFAM deficiency compromises mitochondrial genome maintenance, elevates reactive oxygen species production, and triggers innate immune activation; yet excess accumulation hypercompacts mtDNA, renders it inaccessible, and triggers maladaptive effects in specific disease contexts. The field has learned a humbling lesson: the therapeutic goal is not simply to raise TFAM levels, but to restore its homeostasis. This recalibrated understanding shifts future strategies away from blunt interventions toward molecular approaches that honor the genuine complexity of mitochondrial aging.